Table 7.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1994 to 2003

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 54 67 113 130 157 221 303 307 377 343
Tx with Antirejection Treatments 24 25 38 41 44 57 65 45 43 61
Antibodies Any in Category 66.7% 64.0% 76.3% 61.0% 59.1% 75.4% 53.8% 60.0% 48.8% 65.6%
ALG 20.8% 16.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 4.2% 8.0% 13.2% 17.1% 9.1% 1.8% 1.5% 2.2% 0.0% 3.3%
OKT3 54.2% 48.0% 68.4% 51.2% 47.7% 63.2% 35.4% 26.7% 25.6% 14.8%
Thymoglobulin 0.0% 0.0% 0.0% 0.0% 2.3% 22.8% 21.5% 33.3% 30.2% 45.9%
Zenapax 0.0% 0.0% 0.0% 0.0% 2.3% 1.8% 1.5% 2.2% 2.3% 6.6%
Simulect 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.6% 4.4% 0.0% 4.9%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 27.9%
Corticosteroids Any in Category 37.5% 48.0% 65.8% 78.0% 70.5% 84.2% 87.7% 86.7% 90.7% 67.2%
Steroids 37.5% 48.0% 65.8% 78.0% 70.5% 84.2% 87.7% 86.7% 90.7% 67.2%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.